luteinizing hormone-releasing hormone


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to luteinizing hormone-releasing hormone: luteinizing hormone-releasing hormone agonist

go·nad·o·tro·pin-re·leas·ing hor·mone (GnRH, GRH),

a decapeptide hormone from the hypothalamus that stimulates the anterior pituitary to release both follicle-stimulating hormone and luteinizing hormone. See: gonadotropin-releasing factor.

luteinizing hormone-releasing hormone

(hôr′mōn-rĭ-lē′sĭng)

luteinizing hormone-releasing hormone (LH-RH)

a neurohormone of the hypothalamus that stimulates and regulates the pituitary gland's release of luteinizing hormone.

lu·lib·er·in

(lū-lib'ĕr-in)
A decapeptide hormone from the hypothalamus that stimulates the anterior pituitary to release both follicle-stimulating hormone and luteinizing hormone.
Compare: bioregulator
Synonym(s): luteinizing hormone-releasing hormone.
[luteinizing hormone + L. libero, to free, + -in]
References in periodicals archive ?
Hypothalamic astrocytes respond to transforming growth factor-alpha with secretion of neuroactive substances that stimulate the release of luteinizing hormone-releasing hormone.
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
83, the cost-effectiveness of luteinizing hormone-releasing hormone was less than $50,000 per quality-adjusted life year.
Successful management of vesicouterine fistula by luteinizing hormone-releasing hormone analog.
Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
Vantas is a unique, once-yearly luteinizing hormone-releasing hormone (LHRH) implant indicated for the treatment of prostate cancer, the most prevalent form of cancer afflicting Canadian men
75 mg, 1 month slow release, is an injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer and for the treatment of endometriosis.
Utilizing Valera's Hydron Implant technology, Vantas(TM) has been designed for the continuous 12-month administration of histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH).
Use of a compound such as luteinizing hormone-releasing hormone analogues (GnRH analogues), that disrupts sex steroid signaling (for modifying T cell population makeup or increasing the number of T cells) in a patient in the treatment or prevention of: an autoimmune disease; a hypersensitivity disease; cancer, including where the patient has undergone chemotherapy and/or radiation therapy and/or bone marrow transplantation; an infectious agent, including HIV; organ or bone marrow transplantation rejection; and vaccination against an infectious agent or a tumour cell.
The implant active ingredient, Histrelin, is part of a class of drugs known as luteinizing hormone-releasing hormone (LHRH) agonists.
Zoladex is a luteinizing hormone-releasing hormone analogue (LHRH-A), also known as gonadotropin-releasing hormone (GnRH) agonist.
A controlled trial of bicalutamide (Casodex) versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.

Full browser ?